“Anyways, I still feel like the severity of the acquisitions (accusations) coming from someone with the reputation of RP are serious and add risk to the trade.”

I need someone to explain how RP’s accusations add risk to the trade. Wooden is not the only one to state this. If the lawsuit questioned leronlimab, I’d be concerned, but it doesn’t. The lawsuit also isn’t large enough to cripple CYDY nor is CYDY at risk of losing control of its BOD or control of the company.

I personally disagree and don’t understand how RP’s lawsuit adds risk. Leronlimab is still the same as it was before the lawsuit and the lawsuit does not question leronlimab’s efficacy or patents. Yes, CYDY may have to pay RP $1.3 million and give him shares if he wins the lawsuit. Yes, losing RP was not good for CYDY but I think NP did a good job of filling his role with the Drs that we have for CYDY’s oncology pipeline.